Cystagon, known generically as cysteamine bitartrate, is a medication primarily used in the treatment of nephropathic cystinosis, a rare, inherited metabolic disorder characterized by the accumulation of cystine within cells, leading to damage in various organs, especially the kidneys and eyes. Cystagon works by reducing the levels of cystine in the cells, thereby slowing the progression of kidney disease and preserving kidney function. It is often started in patients diagnosed at a young age to manage the symptoms and complications associated with cystinosis effectively. The medication is taken orally and its dosage is based on the patient's weight and medical condition, requiring careful monitoring by healthcare professionals to optimize treatment outcomes and manage side effects.